

Efficacy and Safety of Relacorilant in Patients With Adrenal Hypercortisolism: Results From a Phase 3 Study

Amir H. Hamrahian,¹ Carmen Aresta.² Corin Badiu,³ Irina Bancos,⁴ Ulrich Dischinger.⁵ Aleksandra Gilis-Januszewska,⁶ Miguel Ángel Mangas Cruz,⁷ John C. Parker,⁸ Rosario Pivonello,⁹ Aurelian-Emil Ranetti,¹⁰ Sergio Rovner,¹¹ Francisco José Tinahones Madueño.¹² Gadi Shlomai.¹³ Austin L. Hand.¹⁴ Andreas G. Moraitis¹⁴

Division of Endocrinology, Diabetes and Metabolism, Johns Hopkins University, Baltimore, MD, USA; ^alstituto Auxologico Italiano, IRCCS, Milan, Italy; ^{as}Carol Davila" University of Medicine and Pharmacy and National Institute of Endocrinology, Bucharest, Romania; ⁴Division of Endocrinology and Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA: 5Department of Internal Medicine, Division of Endocrinology and Diabetes, University Hospital of Würzburg, Germany; 6Chair and Department of Endocrinology, Jagiellonian University, Medical College, Kraków, Poland; 7Hospital Universitario Virgen del Rocio, Sevilla, Spain; [®]Accellacare Clinical Research, Wilmington Health Endocrinology, Wilmington, NC, USA; [®]Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Diabetologia, Andrologia e Nutrizione Università Federico II di Napoli, Naples, Italy; ¹⁰Central Military University Emergency Hospital "Carol Davila," Bucharest, Romania; 11 Frontier Medical Center, El Paso, TX, USA; 12 Hospital Universitario Virgen de la Victoria, Málaga, Spain; 13 Institute of Endocrinology, Diabetes and Metabolism, Sheba Medical Center, Tel Aviv Faculty of Medicine, Ramat Gan, Israel; 14 Corcept Therapeutics Incorporated, Redwood City, CA, USA

Contact: Andreas G. Moraitis (amoraitis@corcept.com)

INTRODUCTION

Relacorilant is a selective glucocorticoid receptor (GR) modulator in development for the treatment of all types of endogenous hypercortisolism (Figure 1) · Competes with cortisol for binding to the GR to modulate

- Figure 1 Relacorilant cortisol activity1-3
- Highly selective for the GR, with no affinity for the progesterone receptor (PR) or other steroid hormone receptors1 Relacorilant has similar effects at the GR as the nonselective GR
- antagonist mifepristone but without the PR-associated off-target effects (eq. endometrial hypertrophy and vaginal bleeding)1-5
- Relacorilant also has no clinically significant impact on adrenocorticotropic hormone (ACTH) levels, resulting in no clinically significant increase in cortisol levels5,
- In the phase 3 GRACE study (NCT03697109) in adults with endogenous hypercortisolism, relacorilant resulted in significant and sustained improvements in hypertension, meeting the study's primary endpoint.3,7 Relacorilant was also well tolerated, with no new safety signals identified3
- Here, we report the results of the phase 3 GRADIENT study (NCT04308590) assessing the safety and efficacy of relacorilant in patients with adrenal hypercortisolism

AIM

GRADIENT assessed the safety and efficacy of relacorilant for the treatment of hypercortisolism in patients with cortisol-secreting adrenal adenomas or hyperplasia, with the primary objective of evaluating blood pressure control GRADIENT evaluated the impact of relacorilant on other cortisol excess-related comorbidities, including glycemic parameters and body composition

METHODS

- · GRADIENT was a double-blind, placebo-controlled study in which individuals aged 18-80 years with cortisol-secreting adrenal adenoma(s) or hyperplasia and hyperglycemia, uncontrolled systolic hypertension, or both were randomized (1:1) to relacorilant or placebo for 22 weeks (Figure 2)
- o Patients had >1.8 µg/dL serum cortisol on either 1-mg overnight or 2-mg 48-hour dexamethasone suppression test (DST), suppressed or low (≤15 pg/mL) early-morning ACTH levels, and a radiologically confirmed benion adrenal lesion
- Systolic hypertension was defined as blood pressure average of ≥130 to ≤170 mm Hg based on 24-hour ambulatory blood pressure monitoring (ABPM)
- Hyperglycemia was defined as type 2 diabetes (fasting plasma glucose ≥126 mg/dL and/or oral glucose tolerance test [oGTT] plasma glucose ≥200 mg/dL at 2 hours, or hemoglobin A1c [HbA1c] ≥6.5%) or impaired glucose tolerance (oGTT plasma glucose ≥140 mg/dL and <200 mg/dL at 2 hours)
- Relacorilant was titrated from 100 mg to 400 mg once daily based on tolerability and efficacy
- The primary endpoints were mean change from baseline to week 22 in 24-hour systolic blood pressure by ABPM for relacorilant versus placebo in patients with hypertension, as well as safety and tolerability
- Secondary and exploratory endpoints included changes in hyperglycemia and body weight/composition
- The Wilcoxon signed-rank test was used for detecting significant changes compared with baseline, and a linear mixed model for repeated measures was used to detect differences between placebo and relacorilant

Figure 2. GRADIENT Study Schema



RESULTS

Baseline Characteristics

 Baseline characteristics are shown in Table 1 · Of the 137 patients randomized to relacorilant or placebo, 41 patients (30%) had hypertension only, 53 patients (39%) had hyperglycemia only, and 43 patients (31%) had both

Table 1. Baseline Patient Characteristics

	Relacorilant (n=68)	Placebo (n=69)
Age, y, median (range)	63.5 (40-79)	64.0 (37-78)
Female, n (%)	50 (73.5)	49 (71.0)
Weight, kg, mean (SD)	89.6 (20.5)	85.9 (20.9)
BMI, kg/m², mean (SD)	33.0 (7.5)	32.3 (8.0)
Waist circumference, cm, mean (SD)	108.2 (16.0)	106.4 (14.8)
Plasma ACTH, pmol/L, median (range) [n]	2.0 (1-7) [67]	2.0 (1-8) [68]
24-hour UFC, μg/dL, median (range) [n]	20.4 (0.0-154.5) [65]	25.6 (0.4-178.7) [66]
LNSC, ng/dL, median (range) [n]	53.0 (50.0-30,500.0) [62]	50.0 (50.0-6,143.0) [64]
Hypertension with or without hyperglycemia, n (%) SBP, mm Hg, mean (SD) [n] ^a DBP, mm Hg, mean (SD) [n] ^a	42 (61.8) 138.8 (9.4) [41] 82.3 (8.7) [41]	42 (60.9) 135.8 (11.2) [42] 82.2 (8.2) [42]
Hyperglycemia ^b with or without hypertension, n (%) HbA1c, %, mean (SD) [n] 2-hour plasma glucose, mg/dL, mean (SD) [n] AUC _{glucose} , h [*] mmol/L, mean (SD) [n]	48 (70.6) 6.5 (1.1) [45] 214.1 (103.1) [47] 23.9 (8.6) [47]	48 (69.6) 6.7 (1.2) [47] 215.0 (75.2) [46] 25.0 (6.1) [46]

Blood Pressure

- In patients with hypertension, systolic blood pressure improved significantly from baseline to week 22 with relacorilant treatment but not with placebo (Table 2)
- The difference between arms was not statistically significant Table 2. Change in Systolic and Diastolic Blood Pressure^a in Patients



- · A subgroup analysis was conducted in study participants who had two abnormal tests: elevated late-night salivary cortisol or urinary free cortisol in addition to post-DST cortisol >1.8 µg/dL (relacorilant, n=26; placebo, n=27)
- Among individuals with hypertension with or without hyperglycemia in this subgroup (relacorilant n=16; placebo n=17);
- o Relacorilant, but not placebo, significantly decreased systolic blood pressure as measured by 24-hour ABPM from baseline to week 22 (P<0.05; Figure 3), with a significant least-squares mean (LSM) difference between arms of -10.4 (95%
- confidence interval [CI], -19.7 to -1.2; P<0.05) . The difference between relacorilant and placebo for diastolic blood pressure
- was also significant at week 22 (LSM, -7.9; 95% CI, -14.4 to -1.5; P<0.05)

ACKNOWLEDGEMENTS

- . The authors want to thank all those who are participating in this study: The study patients and their families, the Investigators and the Sponsor team This study is sponsored by Corcept Therapeutics Incorporated. Medical writing assistance was provided by Tina Schlafly
- PhD, CMPP, of Corcept, and R&R Healthcare Communications

REFERENCES

1. Hunt HJ, et al. J Med Chem. 2017;60(8):3405-3421. 2. Hunt H, et al. Clin Pharmacol Drug Dev. 2018;7(4):408-421. 3. Pivonello R, et al. Presented at: 8th Heart in Diabetes Conference; June 7-9, 2024; Philadelphia, PA, USA. 4. Bali U, et al. J Clin Endocrinol Metab. 2016;101(11):4305-4312. 5. Pivonello R, et al. Front Endocrinol (Lausane). 2021;12:662865. 6. Pivonello R, et al. Presented at: American Association of Clinical Endocrinologists 28th Annual Scientific & Clinical Congress; April 24-28, 2019: Los Angeles, CA, USA, 7, Gilis-Januszewska, et al, Presented at: American Association of Clinical Endocrinologists Middle East North Africa: November 22-24, 2024: Dubai, UAE, 8, He X, et al. Pituitary, 2022;25(3):393-403.









 Relacorilant resulted in significant decreases from baseline to week 22 in daytime systolic and diastolic blood pressure (Figure 4) and nighttime diastolic blood pressure (all P<0.05; Figure 5)

- The LSM difference between relacorilant and placebo for daytime and nighttime systolic blood pressure at week 22 was -10.9 (95% CI, -20.6 to -1.2; P<0.05) and -10.2 (95% CI, -20.9 to 0.5; P=not significant), respectively The LSM difference between the relacorilant and placebo arms for daytime and nighttime diastolic blood pressure
- at week 22 was -8.8 (95% CI, -15.4 to -2.3) and -8.2 (95% CI, -15.7 to -0.7), respectively (both P<0.05)









Glycemic Parameters lycemia with ting glucose, nder the curve eek 22 with I SM acebo for these parameters (all P<0.05; Table 3)

Table 3. Results for Glucose Metabolism Parameters From Baseline to Week 22 for Relacorilant Versus Placebo in Patients With Hyperglycemia With or

Without Hypertension

ting plasma glucose, dL, mean (SD) laseline Veek 22 change from baseline o week 22, mean (SD) <i>P</i> value	125.8 (68.8) 102.1 (21.2) -12.7 (24.5) 0.0026	123.4 (38.7) 124.1 (45.4) 5.3 (30.2) NS	Body weight, kg, m (SD) Baseline Week 22 Change from ba to week 22, mea (SD) P value
l difference relacorilant lacebo (SE) <i>P</i> value	-22.2 0.00		LSM difference relacorilant vs plac (SE) P value
A1c, %, mean (SD) laseline Veek 22 change from baseline o week 22, mean (SD) <i>P</i> value	6.5 (1.1) 6.3 (0.7) -0.2 (0.6) NS	6.7 (1.2) 6.6 (0.9) 0.1 (0.7) NS	Visceral adipose ti mass, g, mean (SE Baseline Week 22 Change from ba to week 22, mea (SD) <i>P</i> value
l difference relacorilant lacebo (SE) <i>P</i> value	-0.3 (0.01		LSM difference relacorilant vs plac (SE)
			P value

23.9 (8.6)

21.1 (6.2)

-1.3(3.8)

0.0365

-2.6(1.3)

0.0459

25.0 (6.

250(7

0.9 (6.1

NS

LSM difference

P value

(SE)

relacorilant vs placebo

Safety and Tolerability 67 and 60 patients in the relacorilant

and placebo groups, respectively,

adverse event (TEAE), the majority of

which were mild to moderate in severity

(relacorilant n=17; placebo n=2) had

TEAEs that resulted in withdrawal of

study drug or premature withdrawal

1 death occurred during the study

and was considered unrelated to

relacorilant (acute mvocardial

Many of the most common TEAEs

reported >1 treatment-emergent

Nineteen (13.9%) patients

from the study

infarction)

Body Composition In the overall study population, relacorilant, but not placebo, resulted in significant weight loss (P<0.0001) and decreased visceral adipose fat mass and volume (both P=0.0001) from baseline to week 22 (Table 4) Comparisons between relacorilant and

> significant for these parameters (all P<0.05) Table 4. Results for Body Composition

Parameters From Baseline to Week 22 for Relacorilant Versus Placebo in the Overall Study Population (ITT)

。	Study Population (111)			reported by patients treated with			
		Relacorilant (n=68)	Placebo (n=69)	relacorilant (Table 5), including myalgia, fatigue, and abdominal			
.7) .4) 2)	Body weight, kg, mean, (SD) Baseline Week 22 Change from baseline to week 22, mean (SD) P value	89.6 (20.5) 87.9 (22.8) -3.6 (4.3)	85.9 (20.9) 86.0 (21.0) -0.0 (3.4) NS	myagia, ratigue, and accomman discomfort, are consistent with cortisol withdrawal, which can occur in individuals with endogenous hypercortisolism after a rapid reduction in exposure to excess cortisol activity precipitated by surgery or medical therapy, particularly when individuals			
	LSM difference relacorilant vs placebo (SE) <i>P</i> value	-3.9 <0.0		 begin treatment⁸ There were no reported cases of relacorilant-induced hypokalemia, adrenal insufficiency, vaginal bleeding 			
))))	Visceral adipose tissue mass, g, mean (SD) Baseline Week 22 Change from baseline to week 22, mean (SD)	1,359.7 (726.4) 1,242.3 (827.7) -161.5 (182.3)	1,579.0 (910.8)	associated with endownetrial hypertrophy, or QT interval prolongati Table 5. TEAEs Occurring in ≥10% of Patients			
	P value	0.0001	NS	TEAE, n (%)	Relacorilant (n=68)	Placebo (n=69)	
	LSM difference relacorilant vs placebo	lacorilant vs placebo		Back pain	21 (30.9)	9 (13.0)	
	(SE)			Fatigue	16 (23.5)	10 (14.5)	
1) 4))	Visceral adipose tissue volume, mL, mean (SD) Baseline Week 22 Change from baseline to week 22, mean (SD) P value			Upper abdominal pain	14 (20.6)	3 (4.3)	
		an (SD) 1,452.9 (767.8) 1,330.3 (877.6) baseline -173.3 (195.1)		Nausea	13 (19.1)	8 (11.6)	
				Pain in extremity	13 (19.1)	5 (7.2)	
				Abdominal pain	12 (17.6)	2 (2.9)	
		0.0001		Dizziness	10 (14.7)	4 (5.8)	
		0.0001	NS	Diarrhea	9 (13.2)	6 (8.7)	

-182.3 (73.1

0.0163

Arthralgi

Asthenia

FAF treatment-en

8 (11.8)

8 (11.8)

7 (10.3)

14 (20.3)

6 (8.7)

12 (17.4)

CONCLUSIONS

 In GRADIENT, relacorilant led to clinically significant improvements in signs and symptoms of endogenous hypercortisolism, including improvements in blood pressure. hyperglycemia, and body weight/composition

- o Greater reductions in systolic blood pressure were observed with relacorilant treatment in the subgroup of patients with 2 abnormal cortisol tests
- o Relacorilant exhibited statistically significant improvements in hyperglycemia, weight loss, and decreased visceral adiposity in all patients
- Relacorilant was well tolerated, and many of the most common adverse events were consistent with cortisol withdrawal

The safety profile of relacorilant was similar to that seen in previous trials in patients with endogenous hypercortisolism of all etiologies

d B) Diastolic Blood Pressure and Hypertension With or				 Among patients with hypergly or without hypertension, fastin HbA1c, and glucose area und 		
T	Ŧ	Т	Ŧ	+0.5	Placebo (Mean BL:	improved from baseline to we relacorilant, with significant L differences at week 22 vs pla

ma/

L SN

vs pl

LSM

AUC

nean, (SD)

Baseline

Week 22

P value

vs placebo (SE)

P value

.h*mmol/L

Change from baseline

to week 22, mean (SD

SM difference relacorilant



Relacorilant (n=48)